Alliance for Multispecialty Research, LLC | AMR Mobile, AL

Research site

(Unclaimed)

Location

100 Memorial Hospital Drive, Annex Building Suite 3B, Mobile, Alabama, United States of America

Site insights

Top conditions

Top treatments

Cytisinicline

Reloxaliase

Allopurinol

Orforglipron

BW-00112

Retatrutide

LY3502970

Parent organization

This site is a part of Alliance for Multispecialty Research, LLC

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 17 total trials

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

The purpose of this study is to learn if modified RNA (modRNA) vaccines for the prevention of influenza are:* safe; and* how these vaccines produce a...

Active, not recruiting

Influenza, Human

Biological: Influenza ModRNA Vaccine

Biological: Quadrivalent Influenza Vaccine (QIV)

Status recently updated

A Study in Patients with Mixed Dyslipidemia

A Phase 2 in Patients With Mixed Dyslipidemia

Not yet enrolling

Enrolling

Mixed Dyslipidemia

Drug: BW-00112

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting

Chronic Kidney Disease

Overweight

Drug: Orforglipron

Drug: Insulin Glargine

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals

The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates tar...

Active, not recruiting

COVID-19

SARS-CoV-2 Infection

Biological: BNT162b2 (Omi XBB.1.5)

Biological: BNT162b2 (Omi JN.1)

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunoge...

Enrolling

Chikungunya Virus Infection

Biological: Placebo booster

Biological: CHIKV VLP vaccine booster

Safety Study of Cytisinicline in Adult Combustible And/or E-cigarette Smokers (ORCA-OL)

Safety assessment of long-term 3 mg cytisinicline three times daily (TID) exposure for 52 weeks is the main purpose of this study, conducted in the U...

Active, not recruiting

Vaping Cessation

Smoking Cessation

Drug: Cytisinicline

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Chronic Kidney Disease (CKD)

Drug: Retatrutide

Drug: Placebo

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients (EURELIA2)

The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the effi...

Enrolling

Hyperuricemia

Tophi

Drug: Allopurinol

Drug: Tigulixostat